Morgan Stanley set a CHF 88 price target on Novartis AG (VTX:NOVN) in a report issued on Tuesday. The firm currently has a buy rating on the stock.

A number of other brokerages have also recently issued reports on NOVN. Deutsche Bank AG set a CHF 83.50 price objective on Novartis AG and gave the stock a neutral rating in a research note on Wednesday, November 8th. set a CHF 90 price objective on Novartis AG and gave the stock a buy rating in a research note on Thursday, September 7th. UBS AG set a CHF 78 price objective on Novartis AG and gave the stock a neutral rating in a research note on Monday, August 28th. Kepler Capital Markets set a CHF 87 target price on Novartis AG and gave the stock a buy rating in a report on Monday, August 28th. Finally, Goldman Sachs Group, Inc. (The) set a CHF 80 target price on Novartis AG and gave the stock a neutral rating in a report on Tuesday, August 8th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of Hold and an average price target of CHF 86.10.

Novartis AG (VTX:NOVN) traded down CHF 0.20 on Tuesday, reaching CHF 81.90. The company had a trading volume of 1,570,000 shares, compared to its average volume of 4,020,000. Novartis AG has a 12 month low of CHF 67.80 and a 12 month high of CHF 85.40.

COPYRIGHT VIOLATION WARNING: “Novartis AG (NOVN) Given a CHF 88 Price Target by Morgan Stanley Analysts” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/15/novartis-ag-novn-given-a-chf-88-price-target-by-morgan-stanley-analysts.html.

About Novartis AG

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.